NCT05014412
Despite recent progress in treatment of multiple myeloma, additional treatment options are still needed.
We’re hoping to learn more about a study medicine called elranatamab to better understand if it could potentially help treat relapsed/refractory multiple myeloma.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
About the study medicine
About the study medicine
We are researching the safety and effectiveness of the study medicine, elranatamab, given alone (Part 1 and Part 2) or in combination with dexamethasone for a duration of 6 cycles (Part 3) in people who have tried, but not had success with their most recent multiple myeloma therapy or treatments from three different drug classes.
Elranatamab is a type of treatment called a B-cell maturation antigen (BCMA) and it will be given to all participants as a shot given under the skin (called a subcutaneous injection), not through an IV. The study medicine dexamethasone is a treatment with anti-myeloma activity and has been an integral part of most combination regimens in multiple myeloma therapy.
We believe elranatamab could work by binding to T-cells (a type of cell in the immune system) to myeloma cells (cancer cells), potentially causing the immune cells to kill the cancer cells. No placebo is used in this trial.
About the study medicine

What are the benefits and risks of taking part in the MagnetisMM-9 trial?
What are the benefits and risks of taking part in the MagnetisMM-9 trial?
People who take part in clinical trials are key to advancing medical research. By participating in the MagnetisMM-9 trial you will be aiding medical research, which may help others with multiple myeloma in the future.
Over the course of the trial, your health may get better, worse, or stay the same. If you consider taking part in the trial will be given a complete list of risks and possible discomforts before agreeing to participate. As with any therapy, there may be a reaction to the study medicine.
What are the benefits and risks of taking part in the MagnetisMM-9 trial?
